GET4

Across TCGA pan-cancer cohorts, GET4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GET4 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GET4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GET4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where GET4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.214	0.424	.006	22	view →
LUAD	DFS	Median	All	0.491	0.743	.003	18	view →
CCRCC	DFS	Median	All	0.984	0.854	.002	11	view →
LSCC	OS	Median	II,III,IV	0.910	0.757	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GET4–PDAC (DFS)

Open the PDAC breakdown →